Please assess the completion status of the following clinical trial:

Trial Title: COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female of non-childbearing potential or male ≥35 years of age, at the time of signing the informed consent~2. Able and willing to provide informed consent~3. Spirometry-confirmed diagnosis of COPD (FEV1/FVC\<0.7 post-bronchodilator) or computerised tomography (CT) proven bronchiectasis~4. Part 1 only: FEV1 ≥50% predicted at screen 1 (i.e. FEV1 prior to any in-clinic administered short acting bronchodilator)~Exclusion Criteria:~1. Unable to safely use a nebuliser as required by the study according to Investigator's opinion~2. Severe COPD or bronchiectasis defined as FEV1 \<20% or requiring non-invasive ventilation~3. History of methaemoglobinaemia~4. Baseline methaemoglobin concentration (using fingertip sensor) \> 2%~5. Uncontrolled or severe asthma or history of severe bronchospasm~6. Presence of tracheostomy/inability to provide spirometry or contraindication for performing spirometry~7. Allergy to any of the components of the study intervention~8. Participation in other clinical investigations utilising investigational treatment within the last 30 days / 5 half lives whichever is longer~9. Deemed unlikely to be able to adhere to protocol in view of investigator~10. Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial~11. Any unstable, uncontrolled or severe medical condition which in the opinion of the investigator would make the patient unsuitable for the trial~12. Participant lives at home with no other adults in the household (Part 2 only)~13. On long-term non-invasive ventilation and/or at higher risk of bronchospasm~14. Prescribed Nitric Oxide donating agent (Nitroprusside, Isosorbide dinitrate, Isosorbide mononitrate, Naproxcinod, Molsidomine and Linsidomine)~15. Female of childbearing potential~16. Clinical diagnosis of COPD but Screening Visit spirometry at study centre excludes COPD (i.e. FEV1/FVC post bronchodilator ratio is not \<0.7)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): In Part 1a, up to 48 patients will be administered single ascending doses of RESP301 (1-6ml; 8 patients per dose cohort). Provided that individual stopping criteria are not met in ≥3 participants, and there are no serious adverse events that are at least possibly related to RESP301, the next dose cohort can be enrolled. Patients can be enrolled into more than one dose cohort provided they did not meet individual stopping criteria.~In Part 1b, 8 participants will receive RESP301 at MTD determined in Part 1a, with short-acting bronchodilator administered 10min prior to RESP301.~In Part 2, a minimum of 150 patients will be enrolled. This may include patients who took part in Part 1. At least the first 50 patients will receive a test dose of RESP301 before enrolment into the dormant phase. Patients who experience flare-up symptoms while in the dormant phase, may proceed to the treatment phase where they will self-administer RESP301 at home for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).